Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-26T16:11:21.294Z Has data issue: false hasContentIssue false
  • English
  • Français

Patient preferences for pharmacogenetic screening in depression

Published online by Cambridge University Press:  24 January 2008

Louise Herbild ,
Dorte Gyrd-Hansen  and
Mickael Bech
Louise Herbild
Affiliation:
Danish Institute of Health Services Research and University of Southern Denmark
Dorte Gyrd-Hansen
Affiliation:
Danish Institute of Health Services Research and University of Southern Denmark
Mickael Bech
Affiliation:
University of Southern Denmark
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aims of this study were to estimate preferences and willingness-to-pay (WTP) for genetic screening for CYP2D6 polymorphisms among a group of former and currently depressed patients.

Methods: A Web-based discrete choice questionnaire was sent to 89 respondents, age 18–65. Four attributes were included: (i) shifts in antidepressant medication before symptom relief, (ii) time with antidepressant medication without symptom relief, (iii) time with antidepressant medication without symptoms but with adverse side-effects, (iv) cost of genetic screening. We used a switching model with two scenarios, one representing patients’ own treatment history and the other a treatment scenario with genetic screening.

Results: In a main-effects model involving the four attributes all coefficients had the expected sign, indicating that as the number of shifts, price or time without symptom relief, and/or dosage-adjustments increased, the likelihood of choosing the screening test decreased. Price and number of shifts in medicine were significant. Marginal WTP for 5 percent probability of a reduction of one in antidepressant shifts was DKK2,599 (€350).

Conclusions: Patients value reductions in shifts in antidepressants and price when choosing between genetic screening and no screening. They do not focus on how the reductions are provided, nor do they value the genetic information the test provides irrespective of its effect on outcome. Given, that the test is able to provide a reduction of one shift in the number of antidepressant shifts with a probability of 5 percent, WTP for the test exceeds its cost.

Keywords

PharmacogeneticsDepressive disorderHealthcare economics and organizationsPolymorphismGenetic
Type
RESEARCH REPORTS
Information
International Journal of Technology Assessment in Health Care , Volume 24 , Issue 1 , January 2008 , pp. 96 - 103
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Andersson, T, Flockhart, DA, Goldstein, DB, et al. . Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005;78:559–581.Google Scholar
2. Berto, P, D'Ilario, D, Ruffo, P, et al. Depression: Cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ. 2000;3:3–10.3.0.CO;2-H>CrossRefGoogle ScholarPubMed
3. Biosam. Farmakogenetik i Danmark. Biosam. 2003;15.Google Scholar
4. Bridges, JF. Stated preference methods in health care evaluation: An emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2003;2:213–224.Google Scholar
5. Briggs, AH, Wonderling, DE, Mooney, CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327–340.Google Scholar
6. Brook, O, van Hout, H, Nieuwenhuyse, H, Heerdink, E. Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients; a randomized controlled trial. Eur Neuropsychopharmacol. 2003;13:1–9.Google Scholar
7. Brøsen, K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59:5–12.CrossRefGoogle ScholarPubMed
8. Brøsen, K. Klassisk Farmakogenetik. Ugeskr Læger. 2005;167:2143–2146.Google Scholar
9. Caraco, Y. Genes and the response to drugs. N Engl J Med. 2004;351:2867–2869.Google Scholar
10. Chou, WH, Yan, FX, de Leon, J, et al. . Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20:246–251.Google Scholar
11. Cuijpers, P, Smit, F, Oostenbrink, J, et al. . Economic costs of minor depression: A population-based study. Acta Psychiatr Scand 2007;115:229–236.CrossRefGoogle ScholarPubMed
12. Danmarks Statistik. Befolkningens brug af internet 2007. 42nd ed. Danmarks Statistik; 2007.Google Scholar
13. Efron, B, Tibshirani, RJ. Introduction to the bootstrap. 1st ed. London: Chapman & Hall/CRC; 1993.Google Scholar
14. Greenberg, PE, Stiglin, LE, Finkelstein, SN, Berndt, ER. Depression: A neglected major illness. J Clin Psychiatry. 1993;54:419–424.Google Scholar
15. Heller, T, Kirchheiner, J, Armstrong, VW, et al. . AmpliChip CYP450 GeneChip: A new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006;28:673–677.Google Scholar
16. Hensher, D, Rose, JM, Greene, WH. Applied choice analysis—A primer. 1st ed. Cambridge: Cambridge University Press; 2005.CrossRefGoogle Scholar
17. Herbild, L. Working paper: Designing a DCE to outlay patients’ and the publics’ preferences for genetic screening in the treatment of depression. 2007:1 ed. University of Southern Denmark, Institute of Public Health—Health Economics; 2007.Google Scholar
18. Hole, AR. A comparison of approaches to estimating confidence intervals for willingness to pay measures. Health Econ. 2007;16:827–840.CrossRefGoogle ScholarPubMed
19. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.Google Scholar
20. Ingelman-Sundberg, M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol. 2005;207 (Suppl):52–56.Google Scholar
21. Ingelman-Sundberg, M. Email correspondence: Preferences for genetic screening for CYP-polymorphisms. 2007.Google Scholar
22. Ingelman-Sundberg, M, Rodriguez-Antona, C. Pharmacogenetics of drug-metabolizing enzymes: Implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci. 2005;360:1563–1570.Google Scholar
23. Kirchheiner, J, Bertilsson, L, Bruus, H, et al. Individualized medicine—implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry. 2003;36 (Suppl 3):S235–S243.Google ScholarPubMed
24. Kirchheiner, J, Brøsen, K, Dahl, ML, et al. . CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatrica Scand. 2001;104:173–192.Google Scholar
25. Kirchheiner, J, Nickchen, K, Bauer, M, et al. . Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442–473.Google Scholar
26. Kolonien Filadelfia. Laboratoriet i Dianalund. Kolonien Filadelfia Laboratoriet 2007 August 9. Available at: URL: http://www.laboratoriet.epilepsihospitalet.dk/.Google Scholar
27. Kuhfeld, WF. Marketing research methods in SAS experimental design, choice, Conjoint and graphical techniques. TS-722 ed. SAS Institute; 2005.Google Scholar
28. Luppa, M, Heinrich, S, Angermeyer, MC, et al. . Cost-of-illness studies of depression A systematic review. J Affect Disord. 2007;98:29–43.CrossRefGoogle ScholarPubMed
29. Lynch, T, Price, A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–396.Google ScholarPubMed
30. Matchar, DB, Thakur, ME, Grossman, I, et al. . Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 146 ed. Durham, NC: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services: Duke Evidence-based Practice Center; 2006.Google Scholar
31. McCombs, JS, Nichol, MB, Stimmel, GL, et al. . The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51 (Suppl):60–69.Google Scholar
32. Mors, NPO, Børglum, AD. Status og perspektiver inden for psykiatrisk genomisk medicin. Ugeskr Læger. 2005;167:2191–2193.Google Scholar
33. Mortensen, PB. Depressioners epidemiologi [The epidemiology of depression]. In: DSI Institut for Sundhedsvæsen, editor. Depression—en folkesygdom der skal behandles? København: DSI Institut for Sundhedsvæsen; 1999:59–66.Google Scholar
34. Mulder, H, Herder, A, Wilmink, FW, et al. . The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf. 2006;15:107–114.Google Scholar
35. Rasmussen, JO, Christensen, M, Svendsen, JM, et al. . CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest. 2006;66:129–136.Google Scholar
36. Rau, T, Wohlleben, G, Wuttke, H, et al. . CYP2D6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressants–-a pilot study. Clin Pharmacol Ther. 2004;75:386–393.CrossRefGoogle ScholarPubMed
37. Russell, JM, Hawkins, K, Ozminkowski, RJ, et al. . The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65:341–347.Google Scholar
38. Smith, RD, Olsen, JA, Harris, A. A review of methodological issues in the conduct of willingness-to-pay studies in health care I: Construction and specification of the contingent market. working paper 84 ed. Australia: Centre for Health Program Evaluation, Monash University; 1999.Google Scholar
39. Sobocki, P, Ekman, M, Agren, H, et al. The mission is remission: Health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract. 2006;60:791–798.Google Scholar
40. Sobocki, P, Lekander, I, Borgstrom, F, et al. . The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry. 2007;22:146–152.Google Scholar
41. Suh, DC. Consumers’ willingness to pay for pharmacy services that reduce risk of medication-related problems. J Am Pharm Assoc (Wash). 2000;40:818–827.Google Scholar
42. Unützer, J, Katon, WJ, Russo, J, et al. Willingness to pay for depression treatment in primary care. Psychiatr Serv. 2003;54:340–345.CrossRefGoogle ScholarPubMed
43. Wedlund, PJ, de Leon, J. Cytochrome P450 2D6 and antidepressant toxicity and response: What is the evidence? Clin Pharmacol Ther. 2004;75:373–375.Google Scholar
44. Wittchen, H, Jacobi, F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15:357–376.Google Scholar